Biora Therapeutics Q3 2024 GAAP EPS From Continuing Operations $(6.08) May Not Be Comparable To $(3.85) Estimate, Sales $32.00K Miss $210.00K Estimate
Biora Therapeutics Q3 2024 GAAP EPS From Continuing Operations $(6.08) May Not Be Comparable To $(3.85) Estimate, Sales $32.00K Miss $210.00K Estimate
Biora Therapeutics 2024年第三季度持續經營的GAAP每股收益爲$(6.08)，與$(3.85)的估計不可比，銷售額爲3.2萬，低於21萬的估算。
Biora Therapeutics (NASDAQ:BIOR) reported quarterly losses From Continuing Operations of $(6.08) per share which missed the analyst consensus estimate of $(3.85) by 57.92 percent. The company reported quarterly sales of $32.00 thousand which missed the analyst consensus estimate of $210.00 thousand by 84.76 percent.
Biora Therapeutics（納斯達克：BIOR）報告了每股持續經營虧損$(6.08)，低於分析師一致預期$(3.85)，差距達到57.92%。該公司報告的季度銷售額爲$3.2萬，低於分析師一致預期的$21萬，差距達到84.76%。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間